Inhibition of MDSC trafficking with SX-682, a CXCR1/2 inhibitor, enhances NK cell immunotherapy in head and neck cancer models.

CONCLUSIONS: The clinical study of CXCR1/2 inhibitors in combination with adoptively transferred NK cells is warranted.
PMID: 31848188 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - December 16, 2019 Category: Cancer & Oncology Authors: Greene S, Robbins Y, Mydlarz WK, Huynh AP, Schmitt NC, Friedman J, Horn LA, Palena C, Schlom J, Maeda DY, Zebala JA, Clavijo PE, Allen C Tags: Clin Cancer Res Source Type: research